share_log

ShockWave Medical (NASDAQ:SWAV) Shares Down 6.7% Following Insider Selling

ShockWave Medical (NASDAQ:SWAV) Shares Down 6.7% Following Insider Selling

衝擊波醫療公司(納斯達克代碼:SWAV)在內部人士拋售後股價下跌6.7%
Defense World ·  2022/09/23 01:21

ShockWave Medical, Inc. (NASDAQ:SWAV – Get Rating)'s share price traded down 6.7% during trading on Thursday after an insider sold shares in the company. The company traded as low as $264.56 and last traded at $265.72. 6,539 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 485,127 shares. The stock had previously closed at $284.69.

在一名內部人士拋售Shockwave Medical,Inc.股票後,該公司股價週四下跌6.7%。該公司股價最低跌至264.56美元,最新報265.72美元。午盤交易中,有6,539股股票易手,較485,127股的平均成交量下降99%。該股此前收盤報284.69美元。

Specifically, Director Frank T. Watkins sold 3,000 shares of ShockWave Medical stock in a transaction that occurred on Tuesday, September 20th. The shares were sold at an average price of $290.09, for a total value of $870,270.00. Following the completion of the sale, the director now directly owns 9,796 shares in the company, valued at approximately $2,841,721.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other ShockWave Medical news, VP Trinh Phung sold 3,500 shares of ShockWave Medical stock in a transaction that occurred on Friday, August 26th. The shares were sold at an average price of $310.76, for a total transaction of $1,087,660.00. Following the completion of the sale, the vice president now directly owns 25,063 shares in the company, valued at approximately $7,788,577.88. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Frank T. Watkins sold 3,000 shares of ShockWave Medical stock in a transaction that occurred on Tuesday, September 20th. The shares were sold at an average price of $290.09, for a total transaction of $870,270.00. Following the sale, the director now owns 9,796 shares of the company's stock, valued at $2,841,721.64. The disclosure for this sale can be found here. Insiders sold 108,700 shares of company stock worth $30,247,696 in the last three months. Corporate insiders own 3.90% of the company's stock.

具體地説,董事弗蘭克·T·沃特金斯在9月20日(星期二)的一筆交易中出售了3,000股衝擊波醫療公司的股票。這些股票的平均價格為290.09美元,總價值為870,270.00美元。出售完成後,董事現在直接擁有該公司9,796股,價值約2,841,721.64美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,可以通過以下方式獲取美國證券交易委員會網站。在另一則Shockwave Medical新聞中,副總裁Trin h Phung在8月26日星期五的一筆交易中出售了3500股Shockwave Medical股票。這些股票的平均價格為310.76美元,總成交金額為1,087,660.00美元。出售完成後,總裁副總經理目前直接持有該公司25,063股股份,價值約7,788,577.88美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。此外,董事弗蘭克·T·沃特金斯在9月20日(星期二)的一筆交易中出售了3,000股衝擊波醫療公司的股票。這些股票以290.09美元的平均價格出售,總成交金額為870,270.00美元。交易完成後,董事現在持有該公司9,796股股票,價值2,841,721.64美元。關於這次銷售的披露可以找到這裏。過去三個月,內部人士出售了108,700股公司股票,價值30,247,696美元。公司內部人士持有該公司3.90%的股份。

Get
到達
ShockWave Medical
衝擊波醫療
alerts:
警報:

Analysts Set New Price Targets

分析師設定新的價格目標

Several analysts have commented on the stock. Wells Fargo & Company lifted their price objective on shares of ShockWave Medical from $176.00 to $255.00 and gave the company an "overweight" rating in a research note on Tuesday, August 9th. Piper Sandler lifted their price objective on shares of ShockWave Medical from $278.00 to $338.00 and gave the company an "overweight" rating in a research note on Monday, August 29th. Oppenheimer cut shares of ShockWave Medical from a "market perform" rating to an "underperform" rating and set a $165.00 price objective for the company. in a research note on Tuesday, September 6th. Morgan Stanley boosted their target price on shares of ShockWave Medical from $201.00 to $255.00 and gave the company an "equal weight" rating in a research note on Tuesday, August 9th. Finally, Canaccord Genuity Group increased their price target on shares of ShockWave Medical from $232.00 to $256.00 and gave the stock a "buy" rating in a report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $246.50.

幾位分析師對該股發表了評論。8月9日,富國銀行在一份研究報告中將Shockwave Medical的股票目標價從176.00美元上調至255.00美元,並給予該公司“增持”評級。8月29日,派珀·桑德勒在一份研究報告中將Shockwave Medical的股票目標價從278.00美元上調至338.00美元,並給予該公司“增持”評級。奧本海默將Shockwave Medical的股票評級從“市場表現”下調至“表現不佳”,併為該公司設定了165.00美元的目標價。在9月6日星期二的一份研究報告中。8月9日,摩根士丹利在一份研究報告中將Shockwave Medical的目標價從201.00美元上調至255.00美元,並給予該公司“同等權重”的評級。最後,Cancord Genuity Group在8月9日週二的一份報告中將Shockwave Medical的股票目標價從232.00美元上調至256.00美元,並給予該股“買入”評級。一名分析師對該股的評級為賣出,一名分析師給出了持有評級,七名分析師對該股給予了買入評級。根據MarketBeat.com的數據,該股的共識評級為“適度買入”,共識目標價為246.50美元。

ShockWave Medical Stock Performance

衝擊波醫療類股表現

The company has a debt-to-equity ratio of 0.02, a current ratio of 5.32 and a quick ratio of 4.41. The firm has a fifty day simple moving average of $263.66 and a 200 day simple moving average of $208.21. The company has a market capitalization of $9.26 billion, a price-to-earnings ratio of 177.29 and a beta of 1.06.
該公司的負債權益比為0.02,流動比率為5.32,速動比率為4.41。該公司的50日簡單移動均線切入位為263.66美元,200日簡單移動均線切入位為208.21美元。該公司市值為92.6億美元,市盈率為177.29,貝塔係數為1.06.

ShockWave Medical (NASDAQ:SWAV – Get Rating) last issued its quarterly earnings data on Monday, August 8th. The company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.43 by $0.25. ShockWave Medical had a return on equity of 21.25% and a net margin of 15.11%. The company had revenue of $120.70 million for the quarter, compared to analyst estimates of $107.51 million. During the same period last year, the company earned ($0.01) earnings per share. ShockWave Medical's quarterly revenue was up 115.5% compared to the same quarter last year. On average, analysts anticipate that ShockWave Medical, Inc. will post 2.57 earnings per share for the current fiscal year.

衝擊波醫療(納斯達克:SWAV-GET評級)最近一次發佈季度收益數據是在8月8日(星期一)。該公司公佈本季度每股收益為0.68美元,比普遍預期的0.43美元高出0.25美元。Shockwave Medical的股本回報率為21.25%,淨利潤率為15.11%。該公司本季度營收為1.207億美元,而分析師預期為1.0751億美元。去年同期,該公司每股收益為0.01美元。衝擊波醫療公司的季度收入與去年同期相比增長了115.5%。分析師平均預計Shockwave Medical,Inc.本財年每股收益將達到2.57美元。

Institutional Trading of ShockWave Medical

衝擊波醫療的制度性交易

A number of institutional investors have recently made changes to their positions in the company. Federated Hermes Inc. boosted its stake in shares of ShockWave Medical by 65.4% in the second quarter. Federated Hermes Inc. now owns 6,376 shares of the company's stock worth $1,219,000 after acquiring an additional 2,520 shares during the last quarter. O Neil Global Advisors Inc. boosted its stake in shares of ShockWave Medical by 160.8% in the second quarter. O Neil Global Advisors Inc. now owns 10,172 shares of the company's stock worth $1,945,000 after acquiring an additional 6,272 shares during the last quarter. Amundi boosted its stake in shares of ShockWave Medical by 37.9% in the second quarter. Amundi now owns 68,106 shares of the company's stock worth $13,589,000 after acquiring an additional 18,713 shares during the last quarter. M&G Investment Management Ltd. boosted its stake in shares of ShockWave Medical by 5.6% in the second quarter. M&G Investment Management Ltd. now owns 9,098 shares of the company's stock worth $1,738,000 after acquiring an additional 479 shares during the last quarter. Finally, Summit Global Investments boosted its stake in shares of ShockWave Medical by 1.8% in the second quarter. Summit Global Investments now owns 4,890 shares of the company's stock worth $935,000 after acquiring an additional 87 shares during the last quarter. 95.40% of the stock is owned by institutional investors and hedge funds.

一些機構投資者最近對他們在該公司的頭寸進行了調整。聯合愛馬仕公司(Federated Hermes Inc.)在第二季度增持了Shockwave Medical的股份65.4%。聯合愛馬仕公司在上個季度增持了2,520股後,現在持有6,376股該公司股票,價值1,21.9萬美元。O Neil Global Advisors Inc.在第二季度增持了Shockwave Medical的股份160.8%。O Neil Global Advisors Inc.在上個季度增持了6,272股後,現在擁有10,172股該公司股票,價值1,945,000美元。Amundi在第二季度增持了Shockwave Medical的股份37.9%。Amundi在上個季度增持了18,713股後,現在持有68,106股該公司股票,價值13,589,000美元。M&G Investment Management Ltd.在第二季度增持了Shockwave Medical的股份5.6%。M&G Investment Management Ltd.目前持有9,098股該公司股票,價值1,738,000美元,此前該公司在上個季度增持了479股。最後,Summit Global Investments在第二季度將其在Shockwave Medical的持股比例提高了1.8%。頂峯全球投資公司現在擁有4890股該公司的股票,價值93.5萬美元,在上個季度又購買了87股。95.40%的股票由機構投資者和對衝基金持有。

ShockWave Medical Company Profile

衝擊波醫療公司簡介

(Get Rating)

(獲取評級)

ShockWave Medical, Inc, a medical device company, engages in developing and commercializing intravascular lithotripsy technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease (PAD); C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee PAD.

Shockwave Medical,Inc.是一家醫療設備公司,致力於開發和商業化血管內碎石技術,用於治療全球外周血管、冠狀動脈和心臟瓣膜疾病患者的鈣化斑塊。該公司提供用於治療膝關節以上外周動脈疾病(PAD)的M5導管;用於治療冠狀動脈疾病的C2導管;以及用於治療膝蓋以下PAD的S4導管。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on ShockWave Medical (SWAV)
  • The Institutions Hold On To Darden Restaurants International
  • What Steelcase's Earnings Say About the Return to the Office?
  • Is The Golden Age Of Homebuilding Already Over?
  • These 3 Big Dividend Payers Also Boast Strong Price Growth
  • Natural Gas Prices Continue To Rally, These Stocks Should Benefit
  • 免費獲取StockNews.com關於Shockwave Medical(SWAV)的研究報告
  • 這些機構持有達頓餐飲國際公司的股份
  • 斯蒂爾凱斯的收益説明瞭他重返辦公室的原因嗎?
  • 住房建設的黃金時代已經結束了嗎?
  • 這三大股利支付者也擁有強勁的價格增長
  • 天然氣價格繼續回升,這些股票應該會受益

Receive News & Ratings for ShockWave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ShockWave Medical and related companies with MarketBeat.com's FREE daily email newsletter.

接受《衝擊波醫學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對ShockWave Medical和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論